最后更新:
2023年4月20日
Nearly 64 million people worldwide are living with 心 failure (HF) and half will die within five years of diagnosis.1,2 As one of the world’s leading causes of disability and death with devasting impact on healthcare systems and the global economy3,4, it is crucial to develop and deliver innovative solutions to address the gaps that currently exist in the treatment of 心 failure — millions of lives depend on advancing the treatment landscape of this disease.
心 failure is a complex syndrome with current treatments helping to slow HF risks and progression in some, 但并不是所有的病人5,6. 这些未得到满足的医疗需求强调了提高认识的紧迫性, 早期检测, and development of life-saving medicines to address these complexities with straightforward solutions.
加深对 高频驱动器 will help to address the unique treatment needs across the spectrum of left ventricular ejection fraction (LVEF) and beyond.
Increasing our understanding of the different mechanisms that cause HF and how to approach them is an urgent but difficult challenge. HF is a complex syndrome often complicated by multiple interrelated 疾病 that may require different management strategies.7
有几种类型的心衰通常由LVEF定义, 测量心脏每次收缩时血液流出的百分比, 包括:EF降低的HF (HFrEF) (LVEF小于或等于40%), HF with mildly reduced EF (HFmrEF) (LVEF 41-49%) and HF with preserved EF (HFpEF) (LVEF greater than or equal to 50%).8,9 大约一半的HF患者有HFmrEF或HFpEF, 治疗选择很少.9-11
Discover the difference between HFpEF vs HFrEF and how we are seeking to uncover the mechanisms of HFpEF in the below video:
另外, 心衰患者的住院率和死亡率仍然高得令人无法接受, 还有一个渐进的, 体力活动能力的衰弱.12-14 These physical symptoms limit patients’ daily activities and can result in poor quality of life, 进一步强调需要协调一致的护理和创新的治疗方案.
As 心 failure 患病率 increases globally, there is a growing need for new innovative solutions. 在澳门在线赌城娱乐, 澳门第一赌城在线娱乐始终坚定不移地致力于推进以患者为中心的科学, while highlighting the importance of early intervention and delivering life-changing medicines for the millions living with 心 failure and other cardiorenal
疾病.
建立心血管、肾脏和代谢(CVRM)状况之间的联系
HF is often complicated by interconnected CVRM 条件s, making it even more difficult to manage.7 多达五分之一的慢性肾脏疾病(CKD)患者会发展为心衰, 这组患者中主要的心血管(CV)并发症.15,16
同样的, hyperkalaemia is also a common complication in those with HF as approximately 3-20% of patients with HF have 
慢性的或复发的 条件.17 LVEF大于50%的HF在高血压患者中也非常普遍, 2型糖尿病(T2D), 肥胖, 或者代谢综合症.10,11,18-20
研究揭示了HF的重要遗传成分, and variants in the genome have been identified to play a role in the development of the disease.21 澳门第一赌城在线娱乐知道心肌病, a heterogeneous gr牛津大学出版社 of 心 muscle 疾病 that include hypertrophic cardiomyopathy (HCM), 扩张型心肌病(DCM), 还有转甲状腺素淀粉样变突变等等, 是HF的重要病因吗.22
This further underlines the importance of connecting the dots between HF’s co-morbidities and disease drivers if we are to truly understand and treat the disease itself.
改变心力衰竭的进程
克服这些挑战和, 最终, 改善患者预后, we must continue to accelerate earlier 检测 and coordinated care that can help address the complexities of 心 failure across the broad spectrum of the disease.
HF guidelines are an important part of the solution as they help provide patient-centric recommendations for clinicians to prevent, 诊断, 并管理心衰患者. 2021年ESC急性和慢性心力衰竭诊断和治疗指南23 and more recently the 2022 American College of Cardiology/American 心 Association/心 Failure Society of America Guidelines for the Management of 心 Failure provide insights on the distinct types of HF, 如何治疗这种疾病, 以及如何及早诊断和干预.11 有效实施是拯救生命的关键.
The complexities of 心 failure require members of the medical community to think and act holistically with a patient-centered approach. We must all drive to the common goal of understanding the nuances of the 心 failure patient journey to advance earlier 检测, intervention and access to innovative treatment approaches that will help 改善患者预后.
早期干预, 检测, 开发挽救生命的药物是推动实现预防目标的必要条件, 停止并可能逆转HF. By increasing awareness of the nuances of HF and the adhering to the latest treatment guidelines, patients can benefit from a treatment plan that aligns with the progression and complexity of their disease, 还有新的治疗方法, 有可能改变疾病的进程.
你可能也喜欢
参考文献
1. Vos T等. 全球, 区域, 全国发病率, 患病率, 195个国家的328种疾病和伤害导致残疾的年数, 1990-2016: 2016年全球疾病负担研究的系统分析. The Lancet 2017; 390(10100):1211–59.
2. Mozaffarian D等. 心 Disease and Stroke Statistics-2016 Update: A Report From the American 心 Association. Circulation 2016; 133(4):e38-360.
3. 世界卫生组织[互联网]. WHO reveals leading causes of death and disability worldwide: 2000-2019; 2020 [cited 2022 August 1]. 可从:http://www获得.谁.int/news/item/09-12-2020-谁-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019#:~:text=心%20disease%20has%20remained%20the,近2000万年% % 20 202019年% 209%.
4. Azad N，等. 老年人群慢性心力衰竭的管理. 老年心脏病. 2014; 11(4):329–37.
5. Hobbs FD等. 一般情况下的心力衰竭. BMJ 2000; 320(7235):626–29.
6. 马查J, Dembowska E, Rosik J, Szostak B, Mazurek-Mochol M, Pawlik A. 治疗心力衰竭的新疗法:近期成就综述. 临床风险管理. 2019年1月22日;15:147-155. doi: 10.2147 / TCRM.S179302. PMID: 30774351; PMCID: PMC6348963.
7. Savarese G，等. 心力衰竭药物滴定, 停药, 死亡率和心力衰竭住院风险:一项多国观察性研究, 英国和瑞典). 心脏衰竭. 2021; doi: 10.1002 / ejhf.2271. 打印前Epub. PMID: 34132001
8. 克利夫兰诊所[互联网]. 心 failure; [引自2022年8月1日] Available from: http://my.clevelandclinic.org/health/疾病/17069-心-failure-understanding-心-failure
9. McDonagh T等. 2021 ESC急性和慢性心力衰竭诊断和治疗指南. 欧洲心脏. 2021;00:1-128. (Epub提前打印). [引自2022年8月1日]. 可从:http://academic获得.牛津大学出版社.com/eur心j/advance-article/doi/10.1093 / eur心j / ehab368/6358045
10. Dunlay SM，等. 保留射血分数心力衰竭的流行病学. Nat Rev Cardiol 2017;14(10):591–602.
11. Heidenreich PA，等. 2022 AHA/ACC/HFSA Guideline for the Management of 心 Failure: A report of the American College of Cardiology/American 心 Association Joint Committee on Clinical Practice Guidelines. 我是科尔·卡迪诺. 2022;79(17):e263-421.
12. Savarese G，等. 心力衰竭的全球公共卫生负担. 卡故障. 2017;3(1):7-11.
13. 梅奥诊所[互联网]. 心 failure; 2021 [引自2022年8月1日]. 可从:http://www获得.mayoclinic.org/疾病 - 条件s/心 failure/symptoms causes/syc - 20373142.
14. 世界心脏联合会. (互联网). Accelerate Change Together: 心 Failure Gap Review; 2020 [cited 2021 Aug 25].
15. House AA等. 心 failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving 全球 Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95(6):1304–17.
16. 西格尔·L等. 慢性肾脏疾病患者的心力衰竭:一项系统综合综述. Biomed Res Int 2014; 2014:937398.
17. 特朗普J，范德米尔P. 高钾血症:病因学、流行病学和临床意义. 欧洲心脏 Suppl 2019; 21(Suppl A):A6-A11.
18. Triposkiadis F，等. 重新定义心力衰竭合并症的关联和意义. 心脏衰竭 2016;18(7):744–58.
19. Ceriello一, Catrinoiu D, 华摄氏度, 张家港基地F, Dombrowsky交流, 伊萨克·B, Lalic纳米, Prattichizzo F, 施耐尔阿, Seferović点, P瓦伦西, Standl E; D&CVD EASD研究组. 2型糖尿病心力衰竭:筛查、诊断和管理的最新观点. Cardiovasc Diabetol. 2021年11月6日;20(1):218. doi: 10.1186/s12933-021-01408-1. PMID: 34740359; PMCID: PMC8571004.
20. 图尔基B，哈拉德GV. 心 Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. 前沿心血管医学. 2021年8月2日;8:695952. doi: 10.3389 / fcvm.2021.695952. PMID: 34409075; PMCID: PMC8367012.
21. 张国强，张国强，张国强. 心力衰竭的遗传决定因素:事实和数字. 心脏衰竭. 2018年6月;5 (3):211 - 217. doi: 10.1002 / ehf2.12267. Epub 2018 2月19日. PMID: 29457878; PMCID: PMC5933969.
22. 心.org(互联网). 什么是成人心肌病? [引自2022年8月1日]. 可从:http://www获得.心.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults
23. 欧洲心脏病学会[互联网]. ESC急性和慢性心力衰竭诊断和治疗指南.
Veeva ID: Z4-54193
编制日期: 2023年4月